Prospective clinical study on non-invasive prenatal testing for severe thalassemia using tag-labeled targeted capture sequencing combined with a modified Bayesian model
A simple blood test during pregnancy can now reliably detect severe alpha-thalassemia without needing parent genetic data, offering families better choices.
This prospective study validated a cfDNA-based NIPT approach for severe alpha-thalassemia that achieves near-clinical-grade performance (sensitivity 97.89%, specificity 98.56%) without needing parental haplotype data, in a high-prevalence Southeast Asian population. The method provides a practical non-invasive prenatal testing pathway for a common rare disease with significant reproductive and population health burden.
What the study was
- Study design
- Prospective cohort study
- Population
- 452 couples of SEA-type alpha-thalassemia carriers; 442 evaluated
- Sample size
- 442
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Zhonghua Fu Chan Ke Za Zhi
Why it surfaced
Prospective clinical validation (N=442) of cfDNA-based prenatal test for severe thalassemia — a preventable rare disease with high burden in SE Asia. Avoids invasive procedures, no parental haplotype required. Strong diagnostic metrics across all endpoints.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.